NCT00117949已完成2 期
An Open-Label, Multi-Center, Ascending, Single Dose Study Investigating the Pharmacokinetics, Pharmacodynamics and Safety of FE200486
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 82
- 试验地点
- 12
- 主要终点
- Time to Meet Insufficient Testosterone Response
研究概览
简要总结
Population pharmacokinetic and pharmacodynamic data from Study FE200486 CS06 and FE200486 CS02 provided further knowledge of the optimal dose regimens for FE200486 (degarelix). Both studies were to guide dose selection for phase III. In addition, safety and tolerance data were generated.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Each patient must meet the following inclusion criteria before entry into the study:
- •Has given written consent before any study related activity is performed (A study related activity is defined as any procedure that would not have been performed during the normal management of the patient.)
- •Is a male patient with histologically proven adenocarcinoma of the prostate (all stages) in whom endocrine treatment is indicated, except for neoadjuvant hormonal therapy. For patients, prostate-specific antigen (PSA) increases on two consecutive determinations at least 2 weeks apart prior to Visit 1 must be documented.
- •Is at least 18 years.
- •Has an ECOG score of
- •Has a baseline testosterone level within the age specific normal range as measured by the central laboratory.
- •Has a PSA value of 2 ng/mL as measured by the central laboratory.
- •Has a life expectancy of at least 6 months.
排除标准
- •Any patient meeting one or more of the following exclusion criteria will not be entered into the study:
- •Previous or present hormonal management of prostate cancer (surgical castration or other hormonal manipulation, e.g. GnRH agonists, GnRH antagonists, antiandrogens, estrogens, PC-Spec) except for neoadjuvant hormonal therapy of < 6 months duration and completed > 6 months prior to Visit
- •Requires hormonal therapy for neoadjuvant purposes.
- •Is recently (within the last 12 weeks preceding Visit 1) or presently treated with any other drug modifying the testosterone level or function.
- •Is considered to be a candidate for curative therapy, i.e., radical prostatectomy or radiotherapy within 6 months after Visit
- •Has a history of severe asthma requiring daily treatment with inhalation steroids, angioedema or anaphylactic reactions.
- •Has hypersensitivity towards any component of the investigational product.
- •Has had a cancer disease within the last 10 years except for prostate cancer, and surgically removed basocellular or squamous cell carcinoma of the skin.
- •Has a clinically significant neurologic, gastrointestinal, renal, hepatic, cardiovascular, psychological, pulmonary, metabolic, endocrine, hematological, dermatological or infectious disorder or any other condition, including excessive alcohol or drug abuse, which may interfere with trial participation, or which may affect the conclusion of the study, as judged by the investigator.
- •Any clinically significant laboratory abnormalities which, in the judgment of the investigator, would interfere with the patient's participation in this study or evaluation of study results (liver transaminases must be within normal limits).
- •Has a mental incapacity or language barrier precluding adequate understanding or co-operation.
- •Has received an investigational drug within the last 12 weeks preceding Visit
- •Has previously participated in this study.
研究组 & 干预措施
Degarelix 40 mg
Experimental
Degarelix 40 mg (10 mg/mL)
干预措施: Degarelix (Drug)
Degarelix 80 mg
Experimental
Degarelix 80 mg (20 mg/mL)
干预措施: Degarelix (Drug)
Degarelix 120 mg
Experimental
Degarelix 120 mg (30 mg/mL)
干预措施: Degarelix (Drug)
Degarelix 160 mg
Experimental
Degarelix 160 mg (40 mg/mL)
干预措施: Degarelix (Drug)
结局指标
主要结局
Time to Meet Insufficient Testosterone Response
时间窗: 3 months
Figures in the table are Kaplan-Meier estimates of the time to meeting insufficient testosterone response. Insufficient testosterone response was defined as testosterone \>1.0 ng/mL at one visit or testosterone 0.5-1.0 at two consecutive visits.
Number of Participants With Testostestone Serum Levels Below 0.5 ng/mL for at Least 28 Days
时间窗: 28 days
The number of participants suppressed for at least 28 days was defined as the estimated "survival probability" at time=Day 28.
次要结局
- Time to Testosterone Castration (Testosterone ≤0.5 ng/mL).(1, 3, 7, 14, 21, 28, 42 days)
- Number of Participants With Sufficient Testosterone Suppression for at Least 84 Days(3 months)
- Time to 50% Reduction in Prostate-specific Antigen Levels(3 months)
- Time to 90% Reduction in Prostate-specific Antigen Levels(3 months)
- Liver Function Tests(3 months)
研究者
研究点 (12)
Loading locations...
相似试验
已完成
2 期
Study of Subcutaneously Administered Peginesatide in Anemic Cancer Patients Receiving ChemotherapyChemotherapy Induced AnemiaCancerNCT00272662Affymax60
进行中（未招募）
1 期
A First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7507062 in Participants With Systemic Lupus ErythematosusSystemic Lupus ErythematosusNCT05835986Hoffmann-La Roche70
已完成
2 期
PF-06741086 Multiple Dose Study in Severe HemophiliaHemophilia A or BNCT02974855Pfizer27
已完成
1 期
Phase 1 Dose Escalation and PK Study of Cu(II)ATSM in ALS/MNDAmyotrophic Lateral SclerosisMotor Neuron DiseaseNCT02870634Collaborative Medicinal Development Pty Limited50
已完成
4 期
Safety and Pharmacokinetic Study of Intravenous Ibuprofen in Pediatric PatientsPainFeverNCT02583399Cumberland Pharmaceuticals30